Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Huali SuDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0002-8353-5483
Yaogang ZhongDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0001-3742-0418
Liqing HeDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY 40208, USA.ORCID 0000-0002-0428-814X
Feng GengDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-2985-0629
Xinmin YinDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY 40208, USA.
Yongjun KouDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-1096-3161
Cheng-Yao ChiangDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.
Xiaokui MoBiostatistic Center and Department of Biomedical Informatics, College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-9797-2687
Yunzhou FanDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0001-9860-0690
Yanwei LiuDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.
Qiang WangDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-1219-7889
Shino MagakiSection of Neuropathology, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-0433-5759
Timothy F CloughesyDepartment of Neurology (Neuro-Oncology), David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-8656-7483
William H YongDepartment of Pathology and Laboratory Medicine, University of California, Irvine, CA 92697, USA.
Arnab ChakravartiDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.
Xiang ZhangDepartment of Chemistry, Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY 40208, USA.ORCID 0000-0003-1102-6313
Deliang GuoDepartment of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-8359-390X
Funding
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Determining the role of lipid droplets in glioblastoma and their therapeutic potentialR01NS104332 · NINDS · OHIO STATE UNIVERSITY · PI Deliang Guo · 2018 to 2026
$4.2M
Delineating how retinoic acids regulate lipid metabolism in glioblastoma and their resistance mechanismsR01CA240726 · NCI · OHIO STATE UNIVERSITY · PI GUO, DELIANG · 2020 to 2024
$2.2M
Identifying SREBP-1 activation mechanism in glioblastoma and its new role in regulating glutamine metabolismR01NS112935 · NINDS · OHIO STATE UNIVERSITY · PI GUO, DELIANG · 2020 to 2024
$1.8M
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastomaR01CA227874 · NCI · OHIO STATE UNIVERSITY · PI CHAKRAVARTI, ARNAB, GUO, DELIANG · 2019 to 2023
$1.5M
Novel lipid and glutamine metabolism-based combination therapies for glioblastomaR01NS141312 · NINDS · OHIO STATE UNIVERSITY · PI Deliang Guo · 2025 to 2026
Elevated hexosamine biosynthesis fuels tumor growth by facilitating protein and lipid glycosylation. But which enzyme in this pathway is better to serve as an antitumor target remains unclear. Here, we revealed that targeting GFAT1, the rate-limiting enzyme in hexosamine synthesis, exhibits limited inhibitory effects on glioblastoma (GBM), the most lethal brain tumor. This outcome is due to the compensation of NAGK-mediated hexosamine salvage pathway. Unexpectedly, inhibiting PGM3, which controls the flux of both de novo hexosamine synthesis and salvage pathways, down-regulates the expression of other enzymes in this pathway and suppresses SREBP-1, a critical lipogenic transcription factor, effectively inhibiting GBM growth. Unexpectedly, SREBP-1 transcriptionally up-regulates the expression of hexosamine synthesis enzymes, while inhibition of these enzymes in turn down-regulates SREBP-1 activation via reducing N-glycosylation of its transporter, SCAP. Our study identified PGM3 as a promising target for treating GBM. Its inhibition disrupts the SREBP-1 activation-hexosamine synthesis positive feedback regulation to effectively eliminate GBM cells.
Indexed as
Brain NeoplasmsGlioblastomaHexosaminesPhosphoglucomutaseSterol Regulatory Element Binding Protein 1AnimalsCell Line, TumorCell ProliferationFeedback, PhysiologicalGene Expression Regulation, NeoplasticGlycosylationHumansMiceXenograft Model Antitumor AssaysHexosaminesPhosphoglucomutaseSREBF1 protein, humanSterol Regulatory Element Binding Protein 1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting PGM3 abolishes SREBP-1 activation-hexosamine synthesis feedback regulation to effectively suppress brain tumor growth. · full record | OpenQuestion